EllisLab_

Congrats @charlesrudin well deserved 👏🏼👏🏼👏🏼👏🏼

Excited to share our @natgenet.nature.com study showing that epigenetically rewired transposable elements control AML leukemia stem cell properties and patient outcome. Grateful to the team & collaborators. nature.com/articles/s4158…

It took us a while to convince our clinical colleagues but very happy to see science converted to trial on this one. Bring home the win for PCa patients 🤞🏼👏🏼🤞🏼👏🏼

MEVPRO-3 trial: Testing EZH2 inhibition in first-line metastatic hormone-sensitive #ProstateCancer. @neerajaiims @huntsmancancer joins @TDorffOnc @cityofhope to discuss this phase III trial testing ADT + enzalutamide vs ADT + enzalutamide + the EZH2 inhibitor mevrometostat, aiming to keep tumors dependent on AR signaling. #WatchNow on UroToday > bit.ly/4swwBOB #mHSPC

A huge win for @Roche roche.com/about/leadersh…

What a start to @CPDR_Labs Annual Retreat 2026 with ⁦@RongFan8⁩ as our morning keynote speaker

Two great clinicians doing awesome work.

4-Abstract 5004: A-DREAM In mHSPC, continuous ADT remains the standard, but can we safely de-escalate in exceptional responders? Our very own @AtishChoudhury from @DanaFarber will present this phase 2 trial at #ASCO26, evaluating ADT interruption in patients with deep responses to androgen receptor pathway inhibitors. @DanaFarber_GU @ASCO @OncoAlert

NEW: NIH spending on new medical research has fallen roughly $1 billion behind the pace of years past, delaying thousands of scientific projects. @benjmueller @irenatfh nytimes.com/2026/04/22/sci…

@DrChoueiri @DanaFarber_GU It will be interesting to see if this study matches the molecular results noted from the DARANA trial with neoadj enza aacrjournals.org/cancerdiscover…

LBA1/Plenary #ASCO26: PROTEUS trial Perioperative apalutamide + ADT vs. placebo + ADT with radical prostatectomy in HR localized or locally advanced PC Our very own #DrMaryEllenTaplin from @DanaFarber_GU will take the stage at #ASCO26 and present phase 3 PROTEUS trial. This is a key multimodal treatment question and could shift the paradigm on how we think about systemic therapy in the perioperative setting. Dr Taplin has worked on countless Neoadjuvant Strategies in prostate cancer and it is rewarding to see her work materialize at the big stage ! @DanaFarber @DanaFarber_GU @ASCO @OncoAlert

@dechen_lin @CCMB_USC Doing well thanks. Great to see you doing the same

@EllisLab_ @CCMB_USC Thank you! its been a while hope you are doing great!

CCMB would like to congratulate Dr. Dechen Lin on his promotion to Associate Professor of Biomedical Sciences at the Herman Ostrow School of Dentistry of USC! #CCMBUSC #USCResearch #Promotion #CancerResearch

Well deserved. Congrats David and keep up the great work 👏🏼👏🏼

@yu_jindan @jdlicht Congrats Jindan 🎊🎉🎊🎉

So glad to become a member of AAP. With my nominator and sponsor @jdlicht

Reflecting over the past few months I have been lucky enough to give seminars to some great clinicians and scientists. I want to say thank you to all. It is great to sit with so many great minds - especially at the junior level - very inspiring. #FengSymposium, @ASCO GU, @KeystoneSymp, @AACR PCa @oricpharma - Dr. Melissa Junttila @unibern - Dr. Marianna Kruithof-de Julio @UTSWMedCenter - Dr. Doug Strand @CancerLouisiana - Dr. Hari Koul

New preprint alert! Here, Yu Shen introduces SMILE, a conditional diffusion model trained to recognize insulin, glucagon, and CD3 simultaneously from H&E stained pancreas tissue. We use SMILE to 3D reconstruct normal and diabetic pancreatic islets

Two preprints. Two days apart. Same mission: crack the genotype × transcriptome code at single-cell resolution. Let's break this down: Saurty-Seerunghen, Lee et al. (Nam, Martelotto & Grillo teams) – GoT-Multi-Gap for RNA-templated gap filling. Clever enzymatic trick: BstFL polymerase does RT + nick translation to gap-fill between flanking probes on RNA, then ligates. Bolts directly onto probe-based scRNA-seq (think 10x Flex-type workflows). Whole transcriptome + mutation calls from the SAME cell. Multiplexed — target many mutations at once Leverages existing probe-based platforms → low barrier to adoption biorxiv.org/content/10.648… Blattman, Maslah et al. (MSK/Pe'er, Charlinge & Lareau teams) – GIFT Genotyping In Fixed Transcriptomes. This one is a biobank's dream. >99% genotyping accuracy — that's wild. Scales to HUNDREDS of mutations per cell. and THE best part...it works on FFPE 🤯 — unlocks archival clinical samples. Clonal lineage tracing in heterogeneous tumors. biorxiv.org/content/10.648… So how do they compare? Gap filling → elegant chemistry, seamless integration with fresh-sample probe-based scRNA-seq workflows. Minimal disruption to existing pipelines. GIFT → sheer scale + FFPE compatibility. If you have a tumor biobank, this is your ticket to retrospective clonal mapping. Both obliterate the old limitation of choosing between genotype OR transcriptome. The convergence of these approaches means we're entering an era where every single-cell experiment can also be a clonal evolution experiment. 🚀

@AdamSharpMedOnc @scserendipity1 Happy Bday mate

46 today #silverfox 😂

Looking forward to this exciting event

Big news for innovators, founders, and R&D-driven small companies: NIH’s Seed Fund is back in action! Thanks to new legislation, U.S. small businesses are again able to pursue up to $1.4 billion per year in Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) funding to power breakthrough science, build game-changing technologies, and move solutions toward real-world impact. Start planning by checking out the funding opportunity forecasts on Grants.gov. ➡️Funding opportunity forecasts: bit.ly/4ccHkIR 📌Key resources for applicants: bit.ly/3OkyeAA